CryoPort, Inc. (NASDAQ:CYRX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of CryoPort, Inc. (NASDAQ:CYRX) have been given a consensus rating of “Moderate Buy” by the seven analysts that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $11.00.

A number of research firms have recently weighed in on CYRX. UBS Group boosted their target price on CryoPort from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, April 1st. Roth Mkm reissued a “buy” rating and issued a $15.00 target price on shares of CryoPort in a research report on Tuesday, April 1st. Guggenheim restated a “buy” rating and issued a $10.00 price target on shares of CryoPort in a research note on Wednesday, April 16th. Morgan Stanley cut their price target on CryoPort from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Monday, May 5th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of CryoPort in a research note on Thursday, May 8th.

CryoPort Price Performance

CYRX opened at $6.37 on Friday. The stock has a 50-day moving average price of $6.20 and a 200-day moving average price of $6.71. CryoPort has a 12-month low of $4.58 and a 12-month high of $9.93. The company has a current ratio of 5.56, a quick ratio of 5.24 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $319.39 million, a P/E ratio of -2.72 and a beta of 1.85.

CryoPort (NASDAQ:CYRX) last released its earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. CryoPort had a negative return on equity of 11.03% and a negative net margin of 50.15%. The company had revenue of $41.04 million during the quarter, compared to analyst estimates of $56.19 million. Equities analysts predict that CryoPort will post -0.99 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Ramkumar Mandalam sold 5,622 shares of CryoPort stock in a transaction on Monday, June 9th. The stock was sold at an average price of $7.06, for a total transaction of $39,691.32. Following the transaction, the director now directly owns 77,089 shares in the company, valued at approximately $544,248.34. The trade was a 6.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jerrell Shelton sold 69,135 shares of the business’s stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $6.47, for a total value of $447,303.45. Following the completion of the transaction, the chief executive officer now owns 912,419 shares in the company, valued at $5,903,350.93. The trade was a 7.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 425,453 shares of company stock valued at $2,871,027 in the last ninety days. 10.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CryoPort

Several large investors have recently made changes to their positions in the business. Franklin Resources Inc. increased its holdings in shares of CryoPort by 0.4% in the fourth quarter. Franklin Resources Inc. now owns 387,131 shares of the company’s stock worth $3,012,000 after purchasing an additional 1,512 shares during the last quarter. Rhumbline Advisers grew its stake in shares of CryoPort by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock valued at $492,000 after buying an additional 1,764 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of CryoPort by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after buying an additional 2,120 shares during the last quarter. Sierra Summit Advisors LLC grew its stake in shares of CryoPort by 5.0% during the first quarter. Sierra Summit Advisors LLC now owns 45,060 shares of the company’s stock valued at $274,000 after buying an additional 2,150 shares during the last quarter. Finally, Nebula Research & Development LLC boosted its holdings in shares of CryoPort by 21.6% in the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock valued at $97,000 after purchasing an additional 2,207 shares during the period. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.